0
Commentary |

Using Pharmacogenetics to Improve Drug Safety and Efficacy

Susanne B. Haga, PhD; Wylie Burke, MD, PhD
JAMA. 2004;291(23):2869-2871. doi:10.1001/jama.291.23.2869.
Text Size: A A A
Published online

Extract

Pharmacogenetics, the tailoring of drug treatment according to individual genotype, has been widely proclaimed as a first step toward personalized medicine. In this issue of THE JOURNAL, Chasman et al1 report the association of 2 common polymorphisms in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene with reduced efficacy of pravastatin therapy. In a survey of 148 single nucleotide polymorphisms in 10 genes involved in lipid metabolism, carriers of 2 linked SNPs in the HMGCR gene showed significantly smaller reductions in levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol with treatment. Statins, the most potent and widely used cholesterol-lowering drugs, function as competitive inhibitors of HMGCR, the rate-limiting enzyme for cholesterol synthesis. This study is the first to demonstrate the impact of genetic variation in the HMGCR drug target for this popular class of drugs, justifying the need for further study to validate and perhaps translate these findings into the clinical setting.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 23

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();